CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathy

CSL Vifor and Travere Therapeutics, Inc., (NASDAQ: TVTX) today announced that the European Medicines Agency's (EMA) CHMP has recommended approval of sparsentan for the treatment of adults with primary IgAN with a urine protein excretion >1.0 g/day (or urine protein-to-creatinine ratio ≥0.75 g/g). IgAN is a rare kidney disorder and a leading cause of kidney failure. The CHMP opinion provides the basis for the European Commission's final decision regarding CMA for sparsentan. If approved in Europe

Related Keywords

Australia ,New Zealand ,Switzerland ,Melbourne ,Victoria ,Norway ,Liechtenstein ,Iceland ,Emmanuelle Lecomte Brisset ,Fresenius Medical Care ,European Commission ,Vifor International ,Head Of Global Regulatory Affairs ,Drug Administration ,European Union ,Senior Vice President ,Global Regulatory Affairs ,Travere Therapeutics ,Marketing Authorization Application ,Orphan Medicinal Product Designation ,Vifor Fresenius Medical Care Renal Pharma ,Iga Nephropathy ,Csl Vifor ,Treatment Options ,Kidney Failure ,Sparsentan ,Kidney Disorder ,European Medicines Agency ,Treatment Option ,Kidney Function ,Herapeutics ,Urine Protein ,Agan ,Europe ,